Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
July 6, 2020

Gilead Sciences gets EC conditional approval for Veklury to treat Covid-19 disease

Gilead Sciences has secured conditional marketing authorisation from the European Commission for its Veklury (remdesivir) to treat SARS-CoV-2 infection, which is responsible for the Covid-19 disease.

Gilead Sciences has secured EC conditional approval for Veklury to treat Covid-19 disease. (Credit: fernando zhiminaicela from Pixabay)